Samsung Electronics Co., Ltd.

Ajou University Industry-academic Cooperation Foundation

Sang-Min Jeon

Hyeoung-won Seo

Seong-goo Kim

Byung-Hyug Roh

Provided is a composition for treating or ameliorating lung cancer including a glucocorticoid-based compound, a glucocorticoid-based compound and an mTOR inhibitor, or a glucocorticoid-based compound and an AMPK inhibitor as an active ingredient. The glucocorticoid-based compounds inhibit the growth of cancer cells by suppressing NRF2 in KEAP1 mutant lung cancer or KEAP1 and LKB1 mutant lung cancer, and exhibit a more potent anticancer effect when used in combination with the mTOR inhibitor, and thus the compounds can be effectively used as anticancer agents for mutant lung cancer. Further, the glucocorticoid-based compounds exhibit a strong anticancer synergistic effect in a low nutritional state when treated in combination with an AMPK inhibitor in KEAP1 and LKB1 normal lung cancer, and thus the compounds can also be used as an anticancer agent for KEAP1 normal lung cancer.

Pharmaceutical composition for treatment of lung cancer comprising glucocorticoid-based compound

A semiconductor device comprises a semiconductor substrate including a first core region and a second core region between which a cell array region is interposed, a first conductive line and a second conductive line extending to the first core region across the cell array region, and a third conductive line and a fourth conductive line extending to the second core region across the cell array region, wherein a line width of the first through fourth conductive lines is smaller than a resolution limit in a lithography process.

Growing community of inventors

Suwon-si, South Korea

Sang-Min Jeon